Fig. 4

A The expression trends of hsa_circ_0069117, miR-875-3p, and PF4V1after hsa_circ_0069117 overexpressing. B The expression trends of hsa_circ_0069117, miR-875-3p, and PF4V1 after hsa_circ_0069117 knocking-down. C Overexpressing hsa_circ_0069117 could promote the gene expression of PF4V1 but inhibit ERK1 and AKT, which could be reversed by co-transfecting miR-875-3p mimics. D and E Overexpressing hsa_circ_0069117 could promote the protein expression of PF4V1 but inhibit the protein expression and phosphorylation of ERK1 and AKT, which could also be reversed by co-transfecting miR-875-3p mimics. F Knocking-down hsa_circ_0069117 could inhibit the gene expression of PF4V1 but promote ERK1 and AKT, which could be reversed by co-transfecting miR-875-3p inhibitor. G and H Overexpressing hsa_circ_0069117 could promote the protein expression of PF4V1 but inhibit the protein expression and phosphorylation of ERK1 and AKT, which could also be reversed by co-transfecting miR-875-3p inhibitor. (n = 3, ***p < 0.001)